Showing results (1311-1320 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|August 1, 1990
Phase II study of esorubicin (4'deoxydoxorubicin) in anthracycline naive patients with ovarian cancerM D Green, J L Speyer, J C Wernz, et al.
Investigational New Drugs|March 23, 2010
Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancerSang Joon Shin, Jae Heon Jeong, Young Suk Park, et al.
Investigational New Drugs|January 7, 2004
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectumMelanie E Royce, Eric K Rowinsky, Paulo M Hoff, et al.
Investigational New Drugs|July 1, 1992
A phase II study of crisnatol mesylate in patients with ovarian carcinomaR V Smalley, D Goldstein, D Bulkowski, et al.
Investigational New Drugs|July 1, 1992
Phase II trial of 5 day continuous intravenous infusion of 6-thioguanine in patients with recurrent and metastatic squamous cell carcinoma of the head and neckF Kruter, M Eisenberger, V Sinibaldi, et al.
Investigational New Drugs|July 22, 2005
Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinomaPhilip E Shaheen, Walter Stadler, Paul Elson, et al.
Investigational New Drugs|July 22, 2005
Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancerAfshin Dowlati, Robert Chapman, Shanmuga Subbiah, et al.
Investigational New Drugs|July 22, 2005
A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumorsG A Otterson, J Lavelle, M A Villalona-Calero, et al.
Investigational New Drugs|July 14, 2005
DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumorsMoritz N Wente, Jörg Kleeff, Markus W Büchler, et al.
Investigational New Drugs|July 14, 2005
Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipidStefan R Vink, Jan H M Schellens, Wim J van Blitterswijk, et al.
Pageof 372